文献速递神经肿瘤小儿神经外科与脑积水

儿童高级别脑干胶质瘤的生存率与预后预测因素:系统综述与Meta分析

Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis.
PubMed 文献 · J Neurooncol · 2017-07-05

该系统综述与Meta分析纳入65项研究(2336例患儿),评估儿童高级别脑干胶质瘤的生存率及预后因素。Meta分析显示1年总生存率为41%(95%CI 38-44%,I²=52%,2083例),2年为15.3%(95%CI 12-20%,I²=73.1%,1329例),3年为7.3%(95%CI 5.2-10%,I²=26%,584例)。亚组分析显示研究日期、肿瘤分类、替莫唑胺使用、非标准干预或1/2期研究与其他研究之间生存结局无差异。

要点

  • 儿童高级别脑干胶质瘤1年总生存率为41%,2年为15.3%,3年为7.3%。
  • 研究日期、肿瘤分类、替莫唑胺使用、非标准干预或研究分期亚组间生存无差异。
  • 年龄、症状持续时间、K27M组蛋白突变及AVCR1突变数据不足,未能行亚组Meta分析。

核心结论

  • 儿童高级别脑干胶质瘤的生存结局仍然很差,且未根据分类、研究分期或不同治疗干预的使用而明显变化。
  • 未来研究应统一结局和预后变量的报告,以便进行准确的Meta分析和更好地探索预后。

研究设计与样本

  • 系统综述与Meta分析,纳入65项研究共2336例患儿,患儿经磁共振成像或活检诊断为高级别脑干胶质瘤并报告总生存率。
  • Meta分析采用二项随机效应模型。

主要发现

  • Meta分析显示1年总生存率为41%(95%CI 38-44%,I²=52%,2083例)。
  • 2年总生存率为15.3%(95%CI 12-20%,I²=73.1%,1329例)。
  • 3年总生存率为7.3%(95%CI 5.2-10%,I²=26%,584例)。
  • 因缺乏报告的变异度量,无法对中位总生存期结果进行Meta分析。
  • 亚组分析比较研究日期、肿瘤分类、替莫唑胺使用、非标准干预或1/2期研究与其他研究,显示生存结局无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因缺乏报告的变异度量,无法对中位总生存期结果进行Meta分析。
  • 患者年龄、症状持续时间、K27M组蛋白突变和AVCR1突变的数据不足,无法进行亚组Meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnosis of a pediatric high grade brain stem glioma is devastating with dismal outcomes. This systematic review and meta-analysis was undertaken to determine the survival rates and assess potential prognostic factors including selected interventions. Studies included involved pediatric participants with high grade brain stem gliomas diagnosed by magnetic resonance imaging or biopsy reporting overall survival rates. Meta-analysis was undertaken using a binomial random effects model. Sixty-five studies (2336 participants) were included. Meta-analysis showed 1 year overall survival (OS) of 41% (95% confidence interval (CI) 38-44%, I-sq 52%, 2083 participants), 2 year OS of 15.3% (95% confidence interval 12-20%, I-sq 73.1%, 1329 participants) and 3 year OS of 7.3% (95% confidence interval 5.2-10%, I-sq 26%, 584 participants). Meta-analyses of median overall survival results was not possible due to the lack of reported measures of variance. Subgroup analysis comparing date of study, classification of tumor, use of temozolomide, non-standard interventions or phase 1/2 versus other studies demonstrated no difference in survival outcomes. There was insufficient data to undertake subgroup meta-analysis of patient age, duration of symptoms, K27M histone mutations and AVCR1 mutations. Survival outcomes of high grade brain stem gliomas have remained very poor, and do not clearly vary according to classification, phase of study or use of different therapeutic interventions. Future studies should harmonize outcome and prognostic variable reporting to enable accurate meta-analysis and better exploration of prognosis.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hassan H, Pinches A, Picton SV, et al. Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. J Neurooncol. 2017. PMID: 28681244. doi:10.1007/s11060-017-2546-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。